BACKGROUND: Several prognostic indices have been devised to optimize patient selection for phase 1 oncology trials with no consensus as to the optimal score and none qualifying as a marker of treatment response. METHODS: Multivariate predictors of overall survival (OS) were tested on 118 referred patients to develop the Hammersmith Score (HS). The score's ability to predict OS, progression-free survival (PFS), and 90-day mortality (90DM) was compared with other prognostic indices. Changes in HS were recalculated during treatment. RESULTS: Albumin<35 g/L, lactate dehydrogenase>450 U/L, and sodium<135 mmol/L emerged as independent prognostic factors. These were used with equal weighting to devise the HS, a compound prognostic index ranging from 0 to 3. High (HS=2-3) score predicted worse OS (hazard ratio [HR]=6.5, P<.001), PFS (HR=2.8, P=.01), and 90DM (OR=9.0, P<.001). HS was a more accurate multivariate predictor of OS (HR=6.4, P<.001, C-index=0.72), PFS (HR=2.7, P=.03), and 90DM (area under the ROC curve 0.703) compared with other scores. Worsening of the HS during treatment predicted for shorter OS (P<.001). HS retained prognostic and predictive ability following external validation. CONCLUSIONS: HS is a simple, validated index to optimize patient selection and predict survival benefit from phase 1 oncology treatments. Prospective validation is ongoing.
BACKGROUND: Several prognostic indices have been devised to optimize patient selection for phase 1 oncology trials with no consensus as to the optimal score and none qualifying as a marker of treatment response. METHODS: Multivariate predictors of overall survival (OS) were tested on 118 referred patients to develop the Hammersmith Score (HS). The score's ability to predict OS, progression-free survival (PFS), and 90-day mortality (90DM) was compared with other prognostic indices. Changes in HS were recalculated during treatment. RESULTS: Albumin<35 g/L, lactate dehydrogenase>450 U/L, and sodium<135 mmol/L emerged as independent prognostic factors. These were used with equal weighting to devise the HS, a compound prognostic index ranging from 0 to 3. High (HS=2-3) score predicted worse OS (hazard ratio [HR]=6.5, P<.001), PFS (HR=2.8, P=.01), and 90DM (OR=9.0, P<.001). HS was a more accurate multivariate predictor of OS (HR=6.4, P<.001, C-index=0.72), PFS (HR=2.7, P=.03), and 90DM (area under the ROC curve 0.703) compared with other scores. Worsening of the HS during treatment predicted for shorter OS (P<.001). HS retained prognostic and predictive ability following external validation. CONCLUSIONS: HS is a simple, validated index to optimize patient selection and predict survival benefit from phase 1 oncology treatments. Prospective validation is ongoing.
Authors: Holly A Massett; Grace Mishkin; Larry Rubinstein; S Percy Ivy; Andrea Denicoff; Elizabeth Godwin; Kate DiPiazza; Jennifer Bolognese; James A Zwiebel; Jeffrey S Abrams Journal: Clin Cancer Res Date: 2016-07-11 Impact factor: 12.531
Authors: Audrey E Kam; Gopichand Pendurti; Umang H Shah; Mohammad H Ghalib; Imran Chaudhary; Jennifer Chuy; Lakshmi Rajdev; Andreas Kaubisch; Santiago Aparo; Ioannis Mantzaris; Sanjay Goel Journal: Invest New Drugs Date: 2018-10-12 Impact factor: 3.850
Authors: David J Pinato; Chara Stavraka; Michael J Flynn; Martin D Forster; Séan M O'Cathail; Michael J Seckl; Rebecca S Kristeleit; David Olmos; Samantha J Turnbull; Sarah P Blagden Journal: PLoS One Date: 2014-01-07 Impact factor: 3.240
Authors: R Kumar; E Geuna; V Michalarea; M Guardascione; U Naumann; D Lorente; S B Kaye; J S de Bono Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640
Authors: Joeri A J Douma; Laurien M Buffart; Ramy Sedhom; Mariette Labots; Willemien C Menke-van der Houven van Oordt; Mikkjal Skardhamar; Anthony De Felice; Esther Lee; Divya Dharmaraj; Nilofer S Azad; Michael A Carducci; Henk M W Verheul Journal: Cancers (Basel) Date: 2021-05-11 Impact factor: 6.639
Authors: Thomas Grellety; Sophie Cousin; Louis Letinier; Pauline Bosco-Lévy; Stéphanie Hoppe; Damien Joly; Nicolas Penel; Simone Mathoulin-Pelissier; Antoine Italiano Journal: BMC Cancer Date: 2016-10-04 Impact factor: 4.430
Authors: Daphne Day; Christina Guo; Yada Kanjanapan; Ben Tran; Anna Spreafico; Anthony M Joshua; Lisa Wang; Albiruni R Abdul Razak; Natasha B Leighl; Aaron R Hansen; Marcus O Butler; Lillian L Siu; Jayesh Desai; Philippe L Bedard Journal: JNCI Cancer Spectr Date: 2019-09-19